Tatiana Andia

TL;DR: There is significant variability in the definition and classification of generic drugs in emerging markets and standardization of the definitions is necessary to make international comparisons viable.

TL;DR: The effects of the Colombian policy efforts to control expenditure by controlling prices are investigated and it is concluded that pricing interventions should be implemented along with a strong market monitoring to prevent market distortions such as inappropriate and unnecessary drug use.

TL;DR: It is concluded that pharmaceuticals’ price regulation, state capacity, the behavior of litigants, prescribers and judges, and the economic interests of big-pharma, are variables that have to be incorporated into a rigorous empirical literature capable of assessing the regressive effect of health rights’ litigation.

TL;DR: In this paper, the authors examine three different cases in which health activists lobbied the World Health Organization and its member states to regulate the marketing practices of multinational companies, and argue that the effectiveness of global advocacy in these cases depended on the level of perceived legitimacy of the knowledge supporting the advocates' claims and on the prestige of the experts participating in the campaigns.

TL;DR: In this paper, the current status of regulatory reliance in Latin America and the Caribbean (LAC) by assessing the countries’ regulatory frameworks to approve new medicines, and to ascertain, for each country, which foreign regulators are considered as trusted regulatory authorities to rely on.